D

Dr Corp Ltd
SZSE:301177

Watchlist Manager
Dr Corp Ltd
SZSE:301177
Watchlist
Price: 29.03 CNY -0.51% Market Closed
Market Cap: ¥11.6B

P/S

7.6
Current
24%
More Expensive
vs 3-y average of 6.1

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
7.6
=
Market Cap
¥11.6B
/
Revenue
¥1.5B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
7.6
=
Market Cap
¥11.6B
/
Revenue
¥1.5B

Valuation Scenarios

Dr Corp Ltd is trading above its 3-year average

If P/S returns to its 3-Year Average (6.1), the stock would be worth ¥23.42 (19% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-75%
Maximum Upside
No Upside Scenarios
Average Downside
44%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 7.6 ¥29.03
0%
3-Year Average 6.1 ¥23.42
-19%
5-Year Average 6.1 ¥23.42
-19%
Industry Average 1.9 ¥7.28
-75%
Country Average 2.8 ¥10.54
-64%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥11.6B
/
Oct 2025
¥1.5B
=
7.6
Current
¥11.6B
/
Dec 2025
¥1.6B
=
7.4
Forward
¥11.6B
/
Dec 2026
¥1.7B
=
6.7
Forward
¥11.6B
/
Dec 2027
¥2.1B
=
5.6
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Dr Corp Ltd
SZSE:301177
11.6B CNY 7.6 85.8
FR
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
224.1B EUR 2.8 20.6
FR
Hermes International SCA
PAR:RMS
170.2B EUR 10.6 37.6
KR
SBW
KRX:102280
235.5T KRW 2 563.1 -117 637.1
CH
Compagnie Financiere Richemont SA
SIX:CFR
87.3B CHF 4.4 23.5
FR
EssilorLuxottica SA
PAR:EL
84B EUR 2.9 36.3
FR
Christian Dior SE
PAR:CDI
76.7B EUR 0.9 16.9
IN
Titan Company Ltd
NSE:TITAN
3.9T INR 5.1 81.6
FR
Kering SA
PAR:KER
28.5B EUR 1.9 396.2
DE
Adidas AG
XETRA:ADS
26.3B EUR 1.1 19.7
US
Tapestry Inc
NYSE:TPR
28.9B USD 3.9 55.4
P/E Multiple
Earnings Growth PEG
CN
D
Dr Corp Ltd
SZSE:301177
Average P/E: 77.4
85.8
69%
1.2
FR
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
20.6
11%
1.9
FR
Hermes International SCA
PAR:RMS
37.6
12%
3.1
KR
SBW
KRX:102280
Negative Multiple: -117 637.1 N/A N/A
CH
Compagnie Financiere Richemont SA
SIX:CFR
23.5
16%
1.5
FR
EssilorLuxottica SA
PAR:EL
36.3
26%
1.4
FR
Christian Dior SE
PAR:CDI
16.9
N/A N/A
IN
Titan Company Ltd
NSE:TITAN
81.6
32%
2.6
FR
Kering SA
PAR:KER
396.2
186%
2.1
DE
Adidas AG
XETRA:ADS
19.7
23%
0.9
US
Tapestry Inc
NYSE:TPR
55.4
107%
0.5

Market Distribution

Higher than 80% of companies in China
Percentile
80th
Based on 7 736 companies
80th percentile
7.6
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Dr Corp Ltd
Glance View

In the bustling world of digital transformation, Dr Corp Ltd. has carved out its niche as an innovative leader that specializes in providing advanced software solutions tailored for the healthcare industry. Born out of a vision to streamline medical processes, the company has grown to become a pivotal player in the intersection of technology and medicine. At its core, Dr Corp Ltd. focuses on developing cutting-edge electronic health record systems, telemedicine platforms, and data analytics tools that aim to enhance patient care, streamline operations, and reduce costs for healthcare providers. Their suite of solutions is designed to integrate seamlessly into existing hospital infrastructure, offering medical practitioners intuitive tools for better data management and patient interaction. The revenue model of Dr Corp Ltd. is as sophisticated as its technology, embracing both subscription-based and licensing fees that provide a steady stream of income. Healthcare establishments often subscribe to Dr Corp's flagship software, drawn by its flexibility and ability to scale according to organizational needs. The company also capitalizes on its consulting services, offering bespoke solutions that include training and support to optimize the use of its products. This dual-pronged approach ensures a diversified income stream, allowing Dr Corp Ltd. to continually invest in research and development, staying ahead of technological curves and adapting to the ever-evolving demands of the healthcare industry. As a result, the firm maintains its reputation not only as a service provider but as a crucial partner in healthcare innovations.

Intrinsic Value
17.9 CNY
Overvaluation 38%
Intrinsic Value
Price ¥29.03
D
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett